nvrt
(2)
Daniel Wagner
Daniel (Dan) Wagner is a medical device and biotechnology executive who leads Otolith Labs, the Washington, DC company building the OtoBand, a non-invasive wearable that uses patented non-invasive Vestibular Resonance Therapy (nVRT) to address chronic vertigo. With more than two decades of commercial experience spanning 60-plus countries and roles at Spark Biomedical, Olympus Corporation, HeartSciences and Signature Biologics, Wagner advised Otolith for over five years before joining full-time as Chief Commercial Officer in 2024 and now serves as Chief Executive Officer, steering the company's go-to-market strategy toward a planned market launch.
Otolith Labs
Otolith Labs is a Washington, D.C. medical device company building the first wearable to treat vertigo, motion sickness and virtual-reality sickness. Its patented non-invasive Vestibular Resonance Therapy (nVRT) uses precisely tuned bone-conduction vibrations to interact with the motion sensors of the inner ear, quieting the faulty balance signals that cause dizziness. The head-worn OtoBand has been tested on hundreds of subjects, carries an FDA Breakthrough Device Designation, and is pursuing FDA clearance through the De Novo pathway.